Rigel to Present at 2024 ASCO and EHA Congress

Rigel Pharmaceuticals, Inc. has announced that it will present various studies from its hematology and oncology portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2024 Hybrid Congress. These presentations will feature data on REZLIDHIA® (olutasidenib), a treatment for mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML), and TAVALISSE® (fostamatinib), used for chronic immune thrombocytopenia (ITP). Also included are insights from an ongoing Phase 1b trial of R2891, which targets IRAK1 and IRAK4 in patients with lower-risk myelodysplastic syndrome (LR-MDS) resistant to previous treatments.

The registrational Phase 2 trial for REZLIDHIA has shown promising results with heavily pretreated patients, including those who had prior venetoclax therapy. Rigel's CEO, Raul Rodriguez, emphasized the excitement around presenting five-year data that reinforce REZLIDHIA's efficacy and safety, particularly among elderly patients who pose a treatment challenge.

Key findings from the REZLIDHIA studies include:

1. Durability of Response: Additional data indicate that olutasidenib continues to show durable responses in heavily pretreated patients with mIDH1 AML, even those who are relapsed or refractory (R/R) to venetoclax. The safety profile remains consistent with previous reports.

2. Tolerance in Elderly Patients: Olutasidenib has been generally well-tolerated in elderly R/R mIDH1 AML patients, inducing lasting remissions. This suggests potential benefits for elderly patients who have failed prior AML treatments.

3. Bridging to Transplant: In mIDH1 R/R AML patients, olutasidenib has been effective in achieving remission and has served as a bridge to potentially curative allogeneic transplantation for a significant subset of patients.

4. Post-MPN Patients: The drug was also well tolerated and effective in patients with post-myeloproliferative neoplasms (MPN) mIDH1 AML, a group that often shows poor responses to existing therapies.

In addition to REZLIDHIA, Rigel is also presenting data on TAVALISSE, which has shown efficacy and safety as a second-line therapy for ITP in real-world settings. The observational study indicated that fostamatinib allowed for successful tapering and discontinuation of corticosteroids while maintaining stable platelet counts.

The presentations and publications are scheduled as follows:
- ASCO Annual Meeting: Online and in-person in Chicago, Illinois, from May 31 to June 4, 2024.
- EHA2024 Congress: Online and in-person in Madrid, Spain, from June 13 to June 16, 2024.

The ASCO presentations will cover various aspects of olutasidenib's application, including its final five-year results in mIDH1 AML, its safety and efficacy in elderly patients, and its role as a bridge-to-transplant therapy. Moreover, the Phase 1b trial of IRAK 1/4 inhibition for LR-MDS patients resistant to prior treatments will also be highlighted.

Rigel Pharmaceuticals focuses on discovering, developing, and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Rigel's ongoing commitment to advancing treatments is evident in their extensive clinical trials and robust pipeline of potential products. The company's efforts are geared towards meeting unmet medical needs, particularly in diseases like AML and ITP, where current treatment options are limited.

In summary, Rigel Pharmaceuticals continues to lead in the development of innovative therapies for challenging hematologic conditions, with significant contributions to the fields of AML and ITP through their drugs REZLIDHIA and TAVALISSE.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!